Melinta Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Melinta Therapeutics, Inc.
Cidara Therapeutics has been given a lifeline after Johnson & Johnson’s opt-in on its universal flu prevention treatment – though the big pharma is expected to pass it onto a third party.
Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.
Melinta CEO and a representative of the Infectious Diseases Society of America call on a Senate HELP subcommittee to push for passage of PASTEUR Act. Introduced in the Senate and House for the third time this year, the measure would establish a subscription model to pay drug developers upfront for certain antimicrobials.
Court found FDA erred in finding Melinta received notice of Paragraph IV certification for generic Minocin on date specified by Nexus. Agency will not require Nexus to send a new notice or give Melinta heads up of final approval of the ANDA.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Rib-X Pharmaceuticals, Inc.
- Cempra, Inc. (Cempra Pharmaceuticals, Inc.)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.